Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains
- PMID: 15238435
- DOI: 10.1093/cercor/bhh123
Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains
Abstract
In this immunohistochemical study, the age- and stage-dependent accumulation of advanced glycation end-products (AGEs) in Alzheimer's disease (AD) and their relation to the formation of neurofibrillary tangles and neuronal cell death was investigated. For this purpose, the distribution of AGEs in neurons and glia was analyzed in the auditory association area of superior temporal gyrus (Brodmann area 22) of young and old non-demented controls and compared with early- and late-stage AD. A possible co-localization of AGEs with typical hallmarks of AD, such as hyperphosphorylated tau (as a marker for disturbed kinase/phosphatase activity), nNOS (as a marker for nitroxidative stress) and caspase-3 (as a marker of apoptotic cell death), was also investigated. Our results show that the percentage of AGE-positive neurons (and astroglia) increase both with age and, in AD patients, with the progression of the disease (Braak stages). Interestingly, nearly all if those neurons which show diffuse cytosolic AGE immunoreactivity also contain hyperphosphoryated tau, suggesting a link between AGE accumulation and the formation of early neurofibrillary tangles. Many, but not all, neurons show a co-localization of AGEs with other markers of neurodegeneration, such as nNOS and caspase-3.
Similar articles
-
Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains.Neurobiol Aging. 2007 Jan;28(1):29-41. doi: 10.1016/j.neurobiolaging.2005.11.007. Epub 2006 Jan 19. Neurobiol Aging. 2007. PMID: 16427160
-
Non-tau based neuronal degeneration in Alzheimer's disease -- an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex.Brain Res. 2008 Jun 5;1213:152-65. doi: 10.1016/j.brainres.2008.03.043. Epub 2008 Apr 1. Brain Res. 2008. PMID: 18455153
-
Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease.Acta Neuropathol. 2002 Aug;104(2):113-22. doi: 10.1007/s00401-002-0523-y. Epub 2002 Jun 4. Acta Neuropathol. 2002. PMID: 12111353
-
Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets.Curr Opin Psychiatry. 2008 Nov;21(6):555-61. doi: 10.1097/YCO.0b013e328314b78b. Curr Opin Psychiatry. 2008. PMID: 18852562 Review.
-
Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.Neurobiol Aging. 2011 May;32(5):763-77. doi: 10.1016/j.neurobiolaging.2009.04.016. Epub 2009 May 22. Neurobiol Aging. 2011. PMID: 19464758 Review.
Cited by
-
Differences Between Tg2576 and Wild Type Mice in the NMDA Receptor-Nitric Oxide Pathway After Prolonged Application of a Diet High in Advanced Glycation End Products.Neurochem Res. 2015 Aug;40(8):1709-18. doi: 10.1007/s11064-015-1654-6. Epub 2015 Jul 19. Neurochem Res. 2015. PMID: 26189181
-
Design of an activatable NIR-II nanoprobe for the in vivo elucidation of Alzheimer's disease-related variations in methylglyoxal concentrations.Chem Sci. 2022 Oct 19;13(42):12511-12518. doi: 10.1039/d2sc05242c. eCollection 2022 Nov 2. Chem Sci. 2022. PMID: 36349272 Free PMC article.
-
Synergistic Effect of Flavonoids and Metformin on Protection of the Methylglyoxal-Induced Damage in PC-12 Neuroblastoma Cells: Structure-Activity Relationship and Potential Target.Molecules. 2024 May 14;29(10):2306. doi: 10.3390/molecules29102306. Molecules. 2024. PMID: 38792167 Free PMC article.
-
Cell cycle related signaling in Neuro2a cells proceeds via the receptor for advanced glycation end products.J Neural Transm (Vienna). 2007;114(11):1413-24. doi: 10.1007/s00702-007-0770-0. Epub 2007 Jun 14. J Neural Transm (Vienna). 2007. PMID: 17564756
-
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease.Alzheimer Dis Assoc Disord. 2011 Jul-Sep;25(3):206-12. doi: 10.1097/WAD.0b013e318204b550. Alzheimer Dis Assoc Disord. 2011. PMID: 21192237 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials